

Repligen (RGEN): Post-2Q26 Earnings Fireside Chat

JULY 29, 2026 | 11:00AM ET

Stephens is hosting a conference call for institutional investors with Repligen's management team to discuss 2Q26 EPS results.

About Featured Speakers

Repligen is a leading provider of advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. RGEN's revenue is diversified across product categories (filtration, chromatography, protein A, analytics, etc.) and across biologic drug end markets (monoclonal antibodies, recombinant proteins, cell/gene therapy, vaccines, etc.).



Olivier Loeillot: President & CEO

Jason Garland: CFO

Jacob Johnson: VP, IR

Katie Plante: IR

Conference call date and time subject to change. To join the call or to obtain more information, please contact your Stephens sales representative.

Topics of Discussion

- 2Q26 Earnings Results
- Demand Trends
- Onshoring Initiatives

Conference Call Host

Mac Bloch, CFA

Life Science Tools and Pharma

Services

(214) 258-2797

mac.bloch@stephens.com

Stephens

INSTITUTIONAL EQUITIES & RESEARCH

stephens.com

f in X 800-843-9691

© 2026 STEPHENS INC. MEMBER NYSE, SIPC | 111 CENTER STREET, LITTLE ROCK, AR 72201

[UNSUBSCRIBE](#) [EMAIL PREFERENCES](#) [VIEW ONLINE](#)

This announcement has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. The research analyst principally responsible for preparation of this announcement has received compensation that is based on the firm's overall revenue which includes investment banking revenue. To access current disclosures for the companies in this announcement, clients should refer to <http://repligen.com/website/InvestorRelations> or contact your Stephens Inc. representative for additional information. Please also note that the announcement may include one or more links to external or third-party websites. Stephens Inc. has not independently verified the information contained on such websites and can provide no assurance as to the reliability of such information, and there can be no assurance that any opinions expressed on such websites reflect the opinions of Stephens Inc. or its management. Artificial intelligence tools may have been used in the preparation of this material, including assisting in data analysis, pattern recognition, and content drafting for research material. Additional information available upon request.